Benefits of a standardized protocol for axillary management after neoadjuvant chemotherapy in a single center.
DOI:
https://doi.org/10.29289/2594539420220029Keywords:
axillary lymph node, neoadjuvant chemotherapy, downstaging, standardized protocolAbstract
ABSTRACT: Introduction: The axillary lymph node status is one of the most important prognostic factors in breast cancer. For locally advanced tumors, neoadjuvant chemotherapy favors higher rates of breast lumpectomy and downstaging tumor burden of axilla.
The aim of this study was to evaluate the use of a standardized image-guided protocol after neoadjuvant chemotherapy to enable sentinel node dissection in patients with axillary downstaging, avoiding axillary dissection. Methods: Retrospective cohort study of data collected from medical records of patients who underwent neoadjuvant chemotherapy in a single center, from January 2014 to December 2018. The protocol comprises the placement of a metal clip in positive axillary lymph node, in patients with up to two clinically abnormal lymph nodes presented on imaging. After neoadjuvant chemotherapy, and once a radiologic complete response was achieved, sentinel node dissection was performed using blue dye and radiotracer. Axillary dissection were avoided in patients whose clipped sentinel node were negative for metastasis and in patients with three identified and negative sentinel node dissection. Results: A total of 471 patients were analyzed for this study: 303 before and 165 after the implementation of the protocol; 3 cases were excluded. The rate of sentinel node dissection in clinical nodes positive patients was statistically higher in this group when compared to patients treated before the protocol implementation (22.8% vs. 40.8%; p=0.001). Patients with triple negative and HER2-positive tumors underwent sentinel node dissection more frequently when compared to luminal tumors (p=0.03). After multivariate analysis, the variables that were associated with a greater chance of performing sentinel node dissection were clinical staging, type of surgery performed and implementation of the axillary assessment protocol. Conclusions: The results showed that the use of an easily and accessible image-guided protocol can improve sentinel node dissection in selected patients, even if the lymph node was positive previously to neoadjuvant treatment.
Downloads
References
Nguyen TT, Hoskin TL, Day CN, Degnim AC, Jakub JW, Hieken TJ, et al. Decreasing use of axillary dissection in node-positive breast cancer patients treated with neoadjuvant chemotherapy. Ann SurgOncol. 2018;25(9):2596-602. https://doi.org/10.1245/s10434-018-6637-9
Rubovszky G, Horváth Z. Recent advances in the neoadjuvant treatment of breast cancer. J Breast Cancer. 2017;20(2):119-31. https://doi.org/10.4048/jbc.2017.20.2.119
Haffty BG, McCall LM, BallmanKV, McLaughlin S, Jagsi R, Ollila DW, et al. Patterns of local-regional management following neoadjuvant chemotherapy in breast cancer: Results from ACOSOG Z1071 (Alliance). Int J Radiat Oncol Biol Phys. 2016;94(3):493-502. https://doi.org/10.1016/j.ijrobp.2015.11.005
Fleissig A, Fallowfield LJ, Langridge CI, Johnson L, Newcombe RG, Dixon JM, et. al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat. 2006;95(3):279-93. https://doi.org/10.1007/s10549-005-9025-7
Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et. al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455-61. https://doi.org/10.1001/jama.2013.278932
Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609-18. https://doi.org/10.1016/S1470-2045(13)70166-9
Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L, et. al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258-64. https://doi.org/10.1200/JCO.2014.55.7827
Pilewskie M, Morrow M. Axillary Nodal Management Following Neoadjuvant Chemotherapy: A Review. JAMA Oncol. 2017;3(4):549-55. https://doi.org/10.1001/jamaoncol.2016.4163
Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, et. al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072-8. https://doi.org/10.1200/JCO.2015.64.0094
Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et at. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414-22. https://doi.org/10.1200/JCO.2007.10.6823
Osório CABT, Chaves Júnior MA, Soares FA. Assessment of pathological response in breast cancer after neoadjuvant chemotherapy: standardization of adapted protocol. J Bras Patol Med Lab. 2012;48(6): 447-53. https://doi.org/10.1590/S1676-24442012000600010
Mamouch F, Berrada N, Aoullay Z, El Khanoussi B, Errihani H. Inflammatory breast cancer: a literature review. World J Oncol. 2018;9(5-6):129-35. https://doi.org/10.14740/wjon1161
Mauriac L, Durand M, Avril A, Dilhuydy JM. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol. 1991;2(5):347-54. https://doi.org/10.1093/oxfordjournals.annonc.a057953
Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 1990;82(19):1539-45. https://doi.org/10.1093/jnci/82.19.1539
Mamtani A, Barrio AV, King TA, Van Zee KJ, Plitas G, Pilewskie M, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? results of a prospective study. Ann Surg Oncol. 2016;23(11):3467-74. https://doi.org/10.1245/s10434-016-5246-8
Schwartz GF, Tannebaum JE, Jernigan AM, Palazzo JP. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast. Cancer. 2010 Mar 1;116(5):1243-51. https://doi.org/10.1002/cncr.24887
Ecanow JS, Abe H, Newstead GM, Ecanow DB, Jeske JM. Axillary staging of breast cancer: what the radiologist should know. Radiographics. 2013;33(6):1589-612. https://doi.org/10.1148/rg.336125060
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Marina de Paula Canal, Caroline Gomes de Almeida Rocha, Almir Galvão Vieira Bitencourt, Marina Sonagli, Cynthia Aparecida Bueno de Toledo Osório, Monique Celeste Tavares, Solange Moraes Sanches, Fabiana Baroni Alves Makdissi
This work is licensed under a Creative Commons Attribution 4.0 International License.
